Carlyle Group Inc. Phathom Pharmaceuticals, Inc. Call Options Transaction History
Carlyle Group Inc.
- $80.8 Million
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PHAT
# of Institutions
145Shares Held
59.4MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$87.7 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$64.8 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$31.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$25.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.78MShares$24.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $340M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...